Standardized reporting for correlation of cytogenetic and molecular genetic data in AML with clinical data
| Genetic group . | Subsets . |
|---|---|
| Favorable | t(8;21)(q22;q22); RUNX1-RUNX1T1 |
| inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | |
| Mutated NPM1 without FLT3-ITD (normal karyotype) | |
| Mutated CEBPA (normal karyotype) | |
| Intermediate-I* | Mutated NPM1 and FLT3-ITD (normal karyotype) |
| Wild-type NPM1 and FLT3-ITD (normal karyotype) | |
| Wild-type NPM1 without FLT3-ITD (normal karyotype) | |
| Intermediate-II | t(9;11)(p22;q23); MLLT3-MLL |
| Cytogenetic abnormalities not classified as favorable or adverse† | |
| Adverse | inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 |
| t(6;9)(p23;q34); DEK-NUP214 | |
| t(v;11)(v;q23); MLL rearranged | |
| −5 or del(5q); −7; abnl(17p); complex karyotype‡ |
| Genetic group . | Subsets . |
|---|---|
| Favorable | t(8;21)(q22;q22); RUNX1-RUNX1T1 |
| inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | |
| Mutated NPM1 without FLT3-ITD (normal karyotype) | |
| Mutated CEBPA (normal karyotype) | |
| Intermediate-I* | Mutated NPM1 and FLT3-ITD (normal karyotype) |
| Wild-type NPM1 and FLT3-ITD (normal karyotype) | |
| Wild-type NPM1 without FLT3-ITD (normal karyotype) | |
| Intermediate-II | t(9;11)(p22;q23); MLLT3-MLL |
| Cytogenetic abnormalities not classified as favorable or adverse† | |
| Adverse | inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 |
| t(6;9)(p23;q34); DEK-NUP214 | |
| t(v;11)(v;q23); MLL rearranged | |
| −5 or del(5q); −7; abnl(17p); complex karyotype‡ |
Frequencies, response rates, and outcome measures should be reported by genetic group, and, if sufficient numbers are available, by specific subsets indicated; excluding cases of acute promyelocytic leukemia.
Includes all AMLs with normal karyotype except for those included in the favorable subgroup; most of these cases are associated with poor prognosis, but they should be reported separately because of the potential different response to treatment.
For most abnormalities, adequate numbers have not been studied to draw firm conclusions regarding their prognostic significance.
Three or more chromosome abnormalities in the absence of one of the WHO designated recurring translocations or inversions, that is, t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), inv(3) or t(3;3); indicate how many complex karyotype cases have involvement of chromosome arms 5q, 7q, and 17p.